Cardiorenalmetabolic

Many physicians are reluctant to test for Lp(a), in part because they are unclear how to manage patients with elevated levels.

A new Mayo Clinic study questions the benefit of implantable cardioverter-defibrillator use to treat patients with transthyretin cardiac amyloidosis.

The FTC first sued Express Scripts, CVS Caremark, and Optum in 2024, claiming anticompetitive and unfair rebating practices surrounding insulin.

Obesity market overview for employers: data on GLP-1s for obesity, digital solutions, and benefit strategies to control costs and outcomes.

Vutrisiran significantly reduces mortality and cardiovascular events in older patients with ATTR-CM, enhancing quality of life and functional capacity.

A randomized clinical trial found a voice-enabled virtual assistant reduced mental distress and improved quality of life, self-care, and glycemic control.

Explore the evolving GLP-1 landscape with insights from industry experts, shaping future health strategies and plan designs for employers.

Dyslipidemia significantly impacts cardiovascular risk in chronic kidney disease, necessitating tailored lipid management strategies for optimal patient outcomes.

Roy Mathew, MD, discusses integrating nephrology and cardiology to bridge the gap in patient adherence and care delivery.

Patient interaction and enhanced support with clinical pharmacists significantly improved pass rates for a measure of controlling blood pressure compared with usual care.

Multidisciplinary care enhances kidney health and cardiovascular outcomes, but more research into models is needed, said Roy Mathew, MD.

New treatments, care gaps, and cardiac monitoring were major focuses in cardiovascular news this year.

From oncology to cardiology, Institute for Value-Based Medicine® conversations highlighted the ways value-based care is reshaping access, equity, and outcomes.

The cardiac myosin inhibitor is expected to be available in the US in the second half of January 2026.

Genetics played a major role in predicting worsening LVEF, progressing to a dilated cardiomyopathy phenotype, and a combined end point of both.

The meeting included new evidence and expert insights on hormone therapy, AI, and the expanding role of GLP-1 therapies in cardiovascular care.

Intranasal etripamil was approved to self-treat episodes of paroxysmal supraventricular tachycardia, supported by phase 3 RAPID trial data.

Lerodalcibep-liga subcutaneous injection is now approved for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from treatment of individual diseases to team-based, population-focused care.

Semaglutide, sotatercept, and bentracimab trials were attendees’ main focus at the American College of Cardiology 2025 Annual Scientific Session.

Academic and clinical experts convened in New Haven, Connecticut, on October 30, 2025, to discuss the potential of coordinated care and prevention to manage cardio-renal-metabolic (CRM) disease.

Clinicians and health system leaders met in Cleveland, Ohio, on October 23, 2025, to share improvements to value-based care in diabetes and chronic kidney disease.

A phase 2 trial demonstrated substantial weight loss with the long-acting peptide–antibody conjugate, as well as other cardiometabolic improvements.

Experts met in Park City, Utah, on October 7, 2025, to discuss how new technologies can help address chronic kidney disease.

Patients aged 30 to 40 years with type 1 diabetes had the highest risk of sudden cardiac death, according to 2010 data from Denmark.